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Abstract
Introduction: Interleukin (IL)-6-type cytokines exert their effects through activation of the Janus kinase/signal
transducers and activators of transcription (JAK/STAT) signaling cascade. The JAK/STAT pathways play an important
role in rheumatoid arthritis, since JAK inhibitors have exhibited dramatic effects on rheumatoid arthritis (RA) in
clinical trials. In this study, we investigated the molecular effects of a small molecule JAK inhibitor, CP690,550 on
the JAK/STAT signaling pathways and examined the role of JAK kinases in rheumatoid synovitis.
Methods: Fibroblast-like synoviocytes (FLS) were isolated from RA patients and stimulated with recombinant
oncostatin M (OSM). The cellular supernatants were analyzed using cytokine protein chips. IL-6 mRNA and protein
expression were analyzed by real-time PCR method and ELISA, respectively. Protein phosphorylation of rheumatoid
synoviocytes was assessed by Western blot using phospho-specific antibodies.
Results: OSM was found to be a potent inducer of IL-6 in FLS. OSM stimulation elicited rapid phosphorylation of
STATs suggesting activation of the JAK/STAT pathway in FLS. CP690,550 pretreatment completely abrogated the
OSM-induced production of IL-6, as well as OSM-induced JAK/STAT, and activation of mitogen-activated kinases
(MAPKs) in FLS.
Conclusions: These findings suggest that IL-6-type cytokines contribute to rheumatoid synovitis through activation
of the JAK/STAT pathway in rheumatoid synoviocytes. Inhibition of these pro-inflammatory signaling pathways by
CP690,550 could be important in the treatment of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease that is characterized by the activation and prolif-
eration of synovial tissues with associated degradation of
articular cartilage [1]. Synovial fibroblasts are believed to
play an important role in rheumatoid synovitis through
the production of a variety of inflammatory mediators
[2]. Activation of synovial fibroblasts is mediated in
large part by cytokines, such as IL-1 or TNF-a,w h i c h
are produced by monocytes/macrophages [3]. However,
other cytokines likely participate in the process of syno-
vial cell activation. Of the IL-6-related cytokines, oncos-
tatin M (OSM) is another product of macrophages and
activated T cells that is elevated in the synovial fluids of
RA patients [4,5]. Moreover, OSM stimulates chemokine
and matrix metalloproteimase (MMPs) production sug-
gesting its important effects in synovial inflammation
[6]. IL-6-type cytokines exert their effects via the signal
transducer gp130 leading to the activation of the Janus
kinase (JAK)/signal transducer and activator of tran-
scription (STAT) cascade [7]. In brief, the ligand-recep-
tor interaction elicits the assembly of cytokine receptors,
receptor-associated JAKs, which recruit and activate
STAT proteins. Phosphorylated STATs then dimerize,
translocate to the nucleus and direct transcription of the
target genes [8]. Recently, JAK inhibition has been
shown to have a prominent effect on autoimmune dis-
eases [9]. CP690,550 is an orally available JAK antago-
nist that is in development for the treatment of RA and
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recent clinical trial demonstrated that CP690,550 is effi-
cacious in RA, resulting in rapid, significant reductions
in the signs and symptoms of RA [12,13]. The role of
oncostatin M in diseases is less well defined, but recent
studies suggest that it might be involved in inflamma-
tory cell recruitment and cartilage destruction in RA
[14]. In the present study, we used primary human
rheumatoid synoviocytes and demonstrated the induc-
tion of multiple signaling cascades and a critical role of
the JAK/STAT pathway in the oncostatin M-mediated
IL-6 synthesis. Furthermore, we showed that interfer-
ence of the JAK/STAT pathway using CP690,550, a JAK
kinase inhibitor, completely abrogated the OSM-induced
IL-6 production in rheumatoid synoviocytes.
Materials and methods
Patients
All RA patients fulfilled the American College of Rheu-
matology criteria for RA [15]. Synovial tissue samples
were obtained from seven patients with RA during syno-
vectomy. The whole study was approved by the Ethics
Committee of the Nagasaki Medical Center and
informed consent was obtained from each of the
individuals.
Reagents
JAK inhibitor CP690,550 was obtained from Axon Bio-
chemicals (Postbus, Netherlands). Human recombinant
OSM was purchased from R&D Systems (Minneapolis,
MN, USA). Human recombinant IL-6 and soluble IL-6
receptor (sIL-6R) were purchased from Peprotech
(Rocky Hills, NJ, USA). PD98059, SB203580, SP600125
and pyridone 6 (2-tert-butyl-9-fluoro-3,6-dihydro-7H-
benz [h]-imidaz (4,5-f) isoquinoline-7-one) were
obtained from Calbiochem (San Diego, CA, USA). Phos-
pho-specific and pan antibodies against JAK-1
(Tyr1022/1023), JAK-2 (Tyr1007/1008), STAT-1
(Tyr701), STAT-3 (Tyr705), STAT-5 (Tyr694), ERK-1/2
(Thr202/Tyr204), p38 (Thr180/Tyr182), c-Jun N-term-
inal kinase (JNK; Thr183/Tyr185) and b-actin were pur-
chased from Cell Signaling Technology (Beverly, MA,
USA). Phospho-specific and pan antibodies against JAK3
(Tyr980) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA).
Preparation of FLS
Synovial tissue was obtained from patients with RA at
the time of total joint replacement or synovectomy.
Synovium was minced and incubated with 1 mg/ml col-
lagenase type VIII (Sigma-Aldrich, St. Louis, MO, USA)
in serum-free RPMI 1640 medium (Life Technologies,
Grand Island, NY, USA) for one hour at 37°C, filtered,
extensively washed, and cultured in DMEM (Life
Technologies) supplemented with 10% FBS in a humidi-
fied 5% CO2 atmosphere. FLS were used from passages
4 through 5 during which time they were a homoge-
neous population of cells (<1% CD 45 positive).
Cytokine and chemokine assays in synoviocytes-
conditioned medium
The levels of cytokines and chemokines in FLS-condi-
t i o n e dm e d i aw e r em e a s u r e du s i n gaR a y B i oH u m a n
Cytokine Antibody Array 5 (Ray Biotech, Inc. Norcross,
GA, USA), according to the manufacturer’s instructions.
This assay employs a qualitative Western screening
technique. The standard array matrix consisted of an 11
× 8 dot grid on a 20 mm × 30 mm nitrocellulose mem-
brane with 79 unique capture antibodies. The array kit
included the biotinylated-antibodies solution and chemi-
luminescent substrate. The cytokine array membrane
was incubated with 1 ml of rheumatoid synoviocyte-
conditioned media for two hours, and the membrane
was then washed three times with washing buffer 1 for
five minutes each, followed by washing buffer II for five
minutes each. Cytokines were detected using cytokine
antibody for one hour, followed by HRP-labeled strepa-
vidin incubation for one hour. The dilution used for
each of these reagents was indicated by the instructions
contained in the assay kit. Reactive spots were visualized
by enhanced chemiluminescence (ECL) (Amersham
Pharmacia Biotech UK Limited, Little Chalfont, UK)
with exposure to X-ray film.
Measurement of cytokine secretion
FLS (5 × 10
4) were seeded in 24-well plates containing
RPMI plus 10% FCS for 24 hours. Following 24 hours of
incubation in serum-free RPMI, the cells were stimu-
lated with OSM for 24 hours. Cell-free supernatants
were collected by centrifugation at 400 g for five min-
utes and assayed for IL-6 with enzyme-linked immuno-
sorbent assay (ELISA) kits (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instructions.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from FLS using the RNeasy
total RNA isolation protocol (Qiagen, Crauley, UK).
cDNA was prepared with Superscript reverse transcrip-
tase (Invitrogen, Grand Island, NY, USA). The amplifi-
cation of the IL-6 transcripts was accomplished on a
Light Cycler (Roche Diagnostics, Mannheim, Germany)
using specific primers. The housekeeping gene fragment
of glyceraldehydes-3-phosphates dehydrogenase
(GAPDH) was used for verification of equal loading.
Cell lysis and Western blotting
Serum-starved FLS were stimulated for 20 min with
OSM indicated in the figure legends and the cells were
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Nonidet P 40, 50 mM Tris, pH 7.5, 100 mM NaCl, 50 mM
NaF, 5 mM EDTA, 20 mM b-glycerophosphate, 1.0 mM
sodium orthovanadate, 10 μg/mL aprotinin and 10 μg/mL
leupeptin) for 20 minutes at 4°C. Insoluble material was
removed by centrifugation at 15,000 × g for 15 minutes at
4°C. The supernatant was saved and the protein concen-
tration was determined using the Bio-Rad protein assay kit
(Bio-Rad, Hercules, CA, USA). An identical amount of
protein (50 μg) for each lysate was subjected to 10% SDS-
polyacrylamide gel electrophoresis, and then transferred to
a nitrocellulose membrane. Western blot analysis using
phospho-specific anti-JAKs, STATs and MAPKs antibo-
dies was performed with an ECL Western blotting kit
(Amersham, Little Chalfont, UK).
Statistical analysis
All quantitative data are presented as the mean ± SD of
independent experiments using different FLSs. Statistical
comparison between treatments was performed using
one-way analysis of variance (ANOVA) and post hoc
Tukey’st e s t .P-values less than 0.05 were considered
statistically significance.
Results
OSM induced IL6 secretion by rheumatoid synoviocytes
We initially examined whether OSM stimulates cytokine
and chemokine production by FLS. The human cytokine/
chemokine protein chip was used to analyze the changes
in the induction of cytokine and chemokine in FLS after
stimulation with OSM. The culture supernatants from
OSM-stimulated FLS in the presence or absence of
CP690,550 were subjected to cytokine/chemokine micro-
array. Data from a representative experiment are depicted
in Figure 1. OSM stimulated the cytokines or chemokines
production from RA-FLS. Among these, we focused on
the cytokine, which was highly induced by OSM and sup-
pressed by CP690,550. OSM stimulated the induction of
IL-6, which was prevented in the presence of CP690,550.
Verification of the array data by real-time PCR and
ELISA analyses confirmed that OSM promotes IL-6
mRNA and protein expression in FLS. The responsive-
ness of FLS to OSM was evaluated by stimulating the
cells with OSM. OSM increased IL-6 mRNA expression
(Figure 2A) and IL-6 protein synthesis (Figure 2B) in RA-
FLS. The minimal dose of 20 ng/ml of OSM was suffi-
cient to induce IL-6 protein synthesis. CP690,550 pre-
treatment abolished the OSM-mediated IL-6 induction in
a dose-dependent manner (Figure 3).
OSM induces activation of the JAK/STAT pathways
To investigate the mechanisms of OSM-mediated signal-
ing in FLS, we evaluated the activation of JAKs and
STATs in OSM-treated synoviocytes. Quiescent FLS
were stimulated with 20 ng/ml of OSM for different
time periods (0 to 40 minutes), and protein extracts
were analyzed by immunoblotting with phosphospecific
antibodies. OSM-stimulated phosphorylation of JAK1,
JAK2, JAK3, STAT1, STAT3 and STAT5, occurred
within 10 minutes and peaked at 20 minutes (Figure 4).
CP690,550 blocked the OSM-induced phosphorylation
of the JAKs and STATs in a dose-dependent manner
(Figure 5A).
Effects of CP690,550 on the MAPK pathways
To investigate the possible interaction between the JAK
and MAPKs pathways, FLS were pretreated with
CP690,550, stimulated with OSM and protein extracts
were analyzed using phospho-specific anti-MAPKs anti-
bodies. OSM stimulated phosphorylation of ERK1/2,
p38 and JNK1/2 and CP690,550 attenuated the phos-
phorylation of these MAPKs in a dose-dependent man-
ner (Figure 5B).
p38 pathway inhibition suppresses OSM-induced IL-6
production
We examined whether MAPK activation was function-
ally linked to the OSM-induced production of IL-6. To
investigate the role of MAPKs in OSM induction of IL-
6 expression, FLS were pre-treated with inhibitors speci-
fic for each of the MAPKs, ERK1/2, p38 and JNK1/2,
and then stimulated with OSM. As shown in Figure 6A,
inhibition of JNK or ERK1/2 signaling led to partial
reduction of the OSM-induced IL-6 secretion without
affecting cellular viability which was checked by trypan
blue exclusion test showing that >95% of cells that were
treated with each inhibitors exclude trypan blue. Mean-
while, inhibition of p38 resulted in an almost complete
abrogation of IL-6 secretion. To determine whether p38
inhibitors affect the expression of IL-6 mRNA, we
examined IL-6 mRNA expression using real-time PCR
methods. SB203580, a p38 specific inhibitor dose-depen-
dently reduced the OSM-stimulated IL-6 mRNA induc-
tion in FLS (Figure 6B).
Pyridone 6 inhibits OSM-induced JAK/STAT activation
To confirm these effects induced by JAK inhibitor,
CP690,550, on RA-FLS, we used a different compound
that blocks JAK. We examined the effects of a pan-JAK
inhibitor, pyridone 6 [16], on OSM-mediated signaling
in RA-FLS. As shown in Figure 7A, pyridone 6 sup-
pressed OSM-induced JAK (1, 2, 3) and STAT (1, 3, 5)
activation in RA-FLS. Also, pyridone 6 inhibited OSM-
induced IL-6 production from RA-FLS (Figure 7B).
Finally, we examined whether CP690,550 affects IL-6
receptor (IL-6R) pathway, which activates STAT3
through gp130. IL-6 plus sIL-6R induced STAT3 activa-
tion in RA-FLS. CP690,550 almost completely inhibited
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FLS (Figure 8).
Discussion
In this study, we demonstrated that OSM activates the
JAK/STAT and MAPK pathways in FLS. Furthermore,
CP690,550 blocked the OSM-induced STAT phosphory-
lation, probably by affecting upstream JAKs. These
results strongly suggest that the JAK/STAT pathways
are essential for OSM-mediated rheumatoid inflamma-
tory responses, and can be blocked by CP690,550. The
IL-6 type cytokine OSM is known to be involved in the
pathogenesis of RA [4]. It is secreted by activated T
cells, monocytes, and neutrophils, and elevated levels of
OSM are detected in the synovial fluid of patients with
RA but not OA [4,5]. OSM is known to activate the
JAK/STAT signaling cascade in other systems [17], but
this has not been properly elucidated in rheumatoid
synoviocytes. Our demonstration of OSM-triggered
phosphorylation of JAKs/STATs in primary rheumatoid
synoviocytes suggests that these cells could be a source
of activated STATs in rheumatoid synovial tissues [18].
CP690,550 is an orally available JAK antagonist that is
currently in development for the treatment of RA and
other autoimmune conditions [11-13]. Blockade of
OSM-induced phosphorylation of JAK1, JAK2 and JAK3
by CP690,550 suggests that this JAK inhibitor also
affected JAK1 and JAK2, in addition to JAK3. This
notion was further supported by the abolishment of
downstream STAT1, STAT3 and STAT5 activation and
OSM-induced IL-6 production in rheumatoid synovio-
cytes. These results suggest the pivotal role of the JAK/
STAT pathway in OSM signaling leading to rheumatoid
inflammatory responses.
The biological agents targeted against tumor necrosis
factor-a (TNF-a) have been shown to successfully
Figure 1 OSM induces IL-6 synthesis from RA-FLS. RA-FLSwere stimulated with recombinant OSM (20 ng/day) in the presence or absence of
CP690,550 (500 nM) for 24 hours. The levels of cytokines and chemokines in RA-FLS-conditioned media were subjected to cytokine antibody
array as described in Material and methods. The indicated dots of cytokines or chemokines were calculated as a relative unit by densitometer.
The dots of each protein of untreated condition (upper column) were assigned the value of 1.0 and the density of each dots of OSM or OSM
plus CP690,550 treated condition (middle or lower column) was expressed as the relative unit. Two experiments were performed using different
RA-FLS and a representative result is shown.
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thought to be more efficacious than disease-modifying
anti-rheumatic drugs (DMARDs) in controlling joint
damage [19]. The combination of DMARDs with biolo-
gical agents can increase the response rate; however,
about 30% of patients do not respond to initial treat-
ment [20]. This has prompted research into alternative
methods to suppress rheumatoid disease activity. JAK3
is critical for signal transduction from the common g-
chain of the receptors for IL-2, IL-4, IL-7, IL-9, IL-15
and IL-21 on the plasma membrane to the nuclei of
immune cells [21]. These cytokines bind to cytokine
receptors and signal through the JAK3-signal transducer
and activator of transcription (STAT) pathways [22].
Therefore, a better understanding of JAK/STAT activa-
tion in the rheumatoid synovium may allow the
development of a novel therapeutic strategy. Agents that
selectively inhibit JAK3 have the potential to mediate
potent immune modulation, affecting lymphocytes,
macrophages and NK cells [23,24]. CP690,550 was ori-
g i n a l l yb e l i e v e dt ob eaJ A K 3i n h i b i t o r .H o w e v e r ,i ti s
now clear that in addition to its effect on JAK3, this
compound inhibits JAK1 and JAK2 at similar concentra-
tions [25]. Interestingly, CP690,550 was shown to be
effective in preventing joint damage in collagen-induced
arthritis (CIA), an animal model of rheumatoid arthritis
[26]. In CIA, IL-6 is a critical cytokine to induce
Figure 2 OSM stimulus IL-6 mRNA expression in RA-FLS, OSM
stimulates IL-6 synthesis in RA-FLS. (a) RA-FLS were stimulated
with 20 ng/ml of recombinant OSM for various times as indicated.
IL-6 and GAPDH mRNA expression was determined by real-time PCR
method. The data were expressed as the mean ± SD of three
independent experiments. *P < 0.01 compared to untreated RA-FLS.
(b) RA-FLS were stimulated with various concentrations of
recombinant OSM as indicated for 24 hours. IL-6 protein in the
conditioned media was determined by ELISA. The data were
expressed as the mean ± SD of three independent experiments. *P
< 0.01 compared to untreated RA-FLS.
Figure 3 CP690,550 suppresses OSM-induced IL-6 synthesis in
RA-FLS; CP690,550 suppresses OSM-induced IL-6 mRNA
expression in RA-FLS. (a) RA-FLS were pretreated with vehicle
(DMSO, -) or indicated concentrations of CP690,550 for two hours.
Cells were stimulated with OSM (20 ng/ml) for 24 hours, after which
conditioned media were collected and IL-6 content was measured
by ELISA. The data were expressed as the mean ± SD of three
independent experiments. *P < 0.05 compared to OSM-treated RA-
FLS. **P < 0.01 compared to OSM-treated RA-FLS. (b) RA-FLS were
pretreated with vehicle (DMSO, -) or indicated concentrations of
CP690,550 for two hours. Cells were stimulated with OSM (20 ng/
ml) for four hours, after which, IL-6 and GAPDH mRNA expression
was determined by real-time PCR method. The data were expressed
as the mean ± SD of three independent experiments. *P < 0.01
compared to OSM-treated RA-FLS. **P < 0.001 compared to OSM-
treated RA-FLS.
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Page 5 of 10Figure 4 Phosphorylation of JAKs/STATs in OSM-treated RA-FLS. Quiescent RA-FLS were stimulated with OSM (20 ng/ml) for indicated
times. Phosphorylation of JAKs (A; JAK1, JAK2, JAK3) and STATs (B; STAT1, STAT3, STAT5) were determined by Western blotting using phospho-
specific or pan antibodies against JAK1, JAK2, JAK3, STAT1, STAT3 and STAT5. Three experiments were performed using different RA-FLS and a
representative result is shown.
Figure 5 CP690,550 suppresses OSM-induced JAKs/STATs activation in RA-FLS; CP690,550 inhibits OSM-induced MAPKs activation RA-
FLS. (a) Quiescent RA-FLS were pretreated with various concentrations of CP690,550 for 2 hours, then stimulated with OSM (20 ng/ml) for 20
minutes. Cellular lysates were subjected to Western blotting using phospho-specific antibodies against JAK1, JAK2, JAK3, STAT1, STAT3 and
STAT5. Three experiments were performed using different RA-FLS and a representative result is shown. (b) Quiescent RA-FLS were pretreated
with various concentrations of CP690,550 for 2 hours, then stimulated with OSM (20 ng/ml) for 20 minutes. Cellular lysates were subjected to
Western blotting using phospho-specific antibodies against ERK1/2, p38 and JNK1/2. Three experiments were performed using different RA-FLS
and a representative result is shown.
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CP690,550 inhibited OSM-induced IL-6 production
from rheumatoid synoviocytes by affecting JAK/STAT
signaling. The exact mechanism by which CP690,550
prevents CIA remains to be determined, it is possible
that CP690,550 inhibits IL-6 induction as well as IL-6-
mediated signaling by affecting the JAK/STAT pathway.
We have provided evidence that CP690,550 is a potent
inhibitor of the JAK/STAT pathway with in vitro activity
in rheumatoid synoviocytes consistent with in vitro
enzyme assay. Although the signaling pathways for IL-6
induction by proinflammatory cytokines and stimuli
have been reported in many cell types [28], no data
have been available on the regulation of IL-6 by OSM-
signaling pathway. Our data clearly demonstrated that
JAK/STAT activation play a pivotal role in OSM-
mediated IL-6 up-regulation in RA. IL-6 is considered
to be a critical cytokine that drives inflammatory joint
destruction in RA [28]. Furthermore, the targeting of
IL-6 has been shown to induce a therapeutic benefit in
RA [29]. CP690,550 could be useful in blocking the
JAK/STAT-mediated proinflammatory responses includ-
ing IL-6-mediated signaling in RA.
The MAPKs play an important role in the induction
of pro-inflammatory cytokines in rheumatoid synovi-
tis [30]. From the experiments using the specific
MAPKs inhibitors, we concluded that OSM-mediated
IL-6 release is weakly dependent on the ERK1/2 or
JNK signaling, but depended mostly on the p38 sig-
naling pathway. Our findings are consistent with pre-
vious studies showing the essential role of p38 in IL-6
production from activated rheumatoid synoviocytes
[31]. Dimerization of IL-6 type cytokine receptors
does not only lead to activation of the JAK/STAT-sig-
naling pathway, but also to the induction of MAPK
[17]. The relationship between the JAK/STAT path-
way and the Ras/MAPK pathway is complex and
these pathways cross at multiple levels [32]. The
molecular mechanism linking JAK/STAT engagement
to the activation of MAPKs remains to be analyzed in
detail. Our findings provide the possibility that p38
M A P Km a yb ep a r t l yi n v o l v e di nt h eJ A K / S T A T -
mediated IL-6 induction.
JAK1 and JAK2 are more widely expressed, whereas
JAK3 expression is mostly limited to haematopietic cell
lines [33]. Although JAK3 has been identified as a
potential therapeutic target in autoimmune disease, its
role in rheumatoid synovitis has not been fully eluci-
dated. In this study, we clearly demonstrated the JAK-
family including JAK3 could be activated in FLS in
response to an IL-6-type cytokine, OSM. Our data sug-
gest that cytokine-activated JAKs in FLS could be an
appropriate therapeutic target in inflammatory arthritis
including RA.
Conclusions
We demonstrated that OSM activates the JAK/STAT
signaling pathway in RA-FLS followed by MAPK activa-
tion leading to the induction of IL-6. CP690,550 blocked
OSM-induced JAK/STAT activation, as well as MAPK
resulting in the abrogation of OSM-responsive induction
Figure 6 p38 inhibition suppresses OSM-induced IL-6
induction; p38 inhibition suppresses OSM-induced IL-6 mRNA
expression. (a) RA-FLS pretreated with vehicle (DMSO-), PD98059
(ERK1/2 pathway inhibitor), SB203580 (p38 inhibitor), and SP600125
(JNK inhibitor) for two hours. Cells were then stimulated with OSM
(20 ng/ml) for 24 hours, after which conditioned media were
collected and IL-6 content was measured by ELISA. The data were
expressed as the mean ± SD of three independent experiments. *P
< 0.01 compared to OSM-treated RA-FLS. **P < 0.001 compared to
OSM-treated RA-FLS. (b) RA-FLS pretreated with vehicle (DMSO-) or
SB203580 (p38 inhibitor), for two hours. Cells were then stimulated
with OSM (20 ng/ml) for four hours, after which IL-6 and GAPDH
mRNA expression was determined by real-time PCR method. The
data were expressed as the mean ± SD of two independent
experiments. *P < 0.05 compared to OSM-treated RA-FLS. **P < 0.01
compared to OSM-treated RA-FLS.
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Page 7 of 10Figure 7 Pyridone 6 suppresses OSM-induced JAKs/STATs activation in RA-FLS; Pyridone 6 suppresses OSM-induced IL-6 synthesis in
RA-FLS. (a) Quiescent RA-FLS were pretreated with vehicle (DMSO -) or pyridone 6 for 2 hours, then stimulated with OSM (20 ng/ml) for 20
minutes. Cellular lysates were subjected to Western blotting using phospho-specific antibodies against JAK1, JAK2, JAK3, STAT1, STAT3 and
STAT5. Two experiments were performed using different RA-FLS and a representative result is shown. (b) Quiescent RA-FLS were pretreated with
vehicle (DMSO, -) or pyridone 6 for two hours, then stimulated with OSM (20 ng/ml) for 24 hours. IL-6 protein in the conditioned media was
determined by ELISA. The data were expressed as the mean ± SD of two independent experiments. *P < 0.05 compared to OSM-treated RA-FLS.
**P < 0.01 compared to OSM-treated RA-FLS.
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Page 8 of 10of IL-6. Therefore, the JAK/STAT pathways are essential
in the transduction of OSM signaling and regulation of
IL-6 genes inRA-FLS. Modulation of the JAK/STAT
pathways by CP690,550 represents an alternative thera-
peutic strategy to regulate rheumatoid inflammation.
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